A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

NCT05720052 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped The study is terminated due to major protocol revisions.

Conditions

Relapsed or Refractory B-cell Lymphoma
Diffuse Large B-cell Lymphoma (DLBCL)
Follicular Lymphoma (FL)
Mantle Cell Lymphoma (MCL)
Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Marginal Zone Lymphoma (MZL)

Interventions

DRUG: MS-553

Sponsor

MingSight Pharmaceuticals, Inc

Collaborators

[object Object]